Business Wire

Veeva Introduces New Capabilities for Remote Drug Sampling in Veeva CRM Engage Meeting

Share

Veeva Systems (NYSE: VEEV) today introduced new remote sampling capabilities in Veeva CRM Engage Meeting. Remote sampling enables field reps to capture and fulfill healthcare professionals’ (HCPs) sample requests, also known as business reply cards (BRCs), while hosting an online meeting. Now companies can complete drug sampling processes during remote meetings in compliance with 21 CFR Part 11 and PDMA requirements.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200422005405/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Doctors can request product samples from field reps through any mobile device or browser. (Graphic: Business Wire)

“Veeva CRM Engage Meeting is powering new ways of working remotely so field reps can help physicians maintain continuity in patient care,” said Arno Sosna, general manager of Veeva CRM. “Our dedication to product excellence and rapid innovation helps Veeva customers quickly deploy new digital capabilities and channels.”

Veeva CRM Engage Meeting makes online meetings with healthcare providers easy and compliant and, now with remote sampling, companies can deliver drug samples without the need for a face-to-face meeting. Reps can confirm license and address information, validate sample details, and save HCP signatures as part of the call record – the same compliant process they would follow during an in-person meeting. HCP signatures can be captured online across any mobile device or browser.

Remote medical inquiry management and consent management are also planned for Veeva CRM Engage Meeting. These new capabilities will allow field reps to compliantly capture and respond to HCP medical inquiries and enable HCPs to approve their communication preferences using Veeva CRM Engage Meeting.

These latest innovations will continue to help the industry in its rapid shift to digital. Since March 2020, Veeva has offered Veeva CRM Engage Meeting free to new customers so they can stay connected with HCPs. During March, life sciences companies connected with more than 100,000 HCPs online,1 up 2,347% compared to January. These remote meetings are also more in-depth, lasting an average of 13 minutes longer2 than a typical face-to-face meeting.3

Remote sampling is available today in Veeva CRM Engage Meeting. Remote medical inquiry management and remote consent are expected to be available in the coming months. To learn more about Veeva CRM Engage Meeting, visit veeva.com/eu/engage-meeting.

Learn how Veeva is helping customers leverage digital to connect with HCPs at the upcoming Veeva Summit on 9 June, 2020. Pre-register for the virtual event and stay up-to-date on program details at veeva.com/Summit.

Additional Information

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 850 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-K for the period ended January 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.


1 Based on internal data from Veeva HCP Pulse
2 Based on internal data from Veeva HCP Pulse
3 Pharma Sales Reps are Struggling – Here’s Why. BlueNovius. May 2018.

® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com

Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Newly Established Samsung Epis Holdings to Drive Growth for Samsung Bioepis and a New Subsidiary3.11.2025 04:17:00 EET | Press release

Samsung Epis Holdings Co., Ltd. today announced its establishment as a new investment holding company, following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics (KRX: 207940.KS). Samsung Epis Holdings will be listed on Korea Exchange (KRX) on November 24, 2025, after establishment of a new subsidiary company on November 14, 2025. Samsung Bioepis will continue to operate its biosimilar business as a 100% owned subsidiary of Samsung Epis Holdings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030908044/en/ Kyung-Ah Kim will serve as the President and Chief Executive Officer (CEO) of Samsung Epis Holdings, in addition to her current role as the President and CEO of Samsung Bioepis. Kyung-Ah Kim will serve as the President and Chief Executive Officer (CEO) of Samsung Epis Holdings, in addition to her current role as the President and CEO of Samsung Bioepis. "The new investment holding company will focus on d

SBC Medical to Announce Q3 2025 Financial Results on November 14 and Hold Earnings Call on November 1731.10.2025 14:00:00 EET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it will release its Q3 2025 financial results on Friday, November 14, 2025, before the U.S. market opens. The Company will hold a Earnings Call on Monday, November 17, 2025 at 5:00 p.m. Eastern Time to discuss the financial results and take questions live. Please register in advance for the conference using the link provided below. https://edge.media-server.com/mmc/p/e2znwqtx It will automatically direct you to the registration page for “SBC Q3 2025 Financial Results Presentation.” Please follow the steps to enter your registration details and click “Submit.” Upon registration, you will be able to access the dedicated conference call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as pas

Motive Brings Seamless eSIM Activation to Luxury European Automotive Brand in Latin America31.10.2025 12:00:00 EET | Press release

Motive, a global leader in connected device lifecycle management and automation, has announced a landmark partnership with a leading operator in Central and South America, bringing seamless and secure mobile connectivity to a luxury European automotive brand’s vehicles in Mexico. The solution—powered by Motive's Entitlement Server—enables the carrier’s subscribers to link their mobile identities directly to their vehicles using embedded SIM (eSIM) technology leveraging GSMA’s mobile connectivity standards. This automotive-first for the Latin America region allows drivers to activate their mobile subscription upon entering a vehicle, delivering a personalized, connected experience on par with their smartphones. Whether for entertainment, navigation, or communication services, users benefit from uninterrupted access to their mobile services with enhanced security and privacy. "This deployment showcases the power of intelligent entitlement and provisioning," said Francisco Viana, VP Sales

Hanshow and Unide Partner to Advance Store Modernization under the “Plan Unide 2.0” Strategy31.10.2025 03:45:00 EET | Press release

Hanshow, a global leader in digital retail solutions, has announced a strategic collaboration with Unide Corporativa, one of Spain’s most established food retail cooperatives, to advance store digitalization and operational efficiency under its new strategic roadmap “Plan Unide 2.0” (2025–2028). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030921658/en/ Founded over 90 years ago, Unide unites hundreds of independent grocery retailers across Spain under a cooperative model built on proximity, freshness, and community service. With Plan Unide 2.0, the cooperative aims to strengthen competitiveness through member business development, store modernization, and new store openings—a roadmap to ensure sustainable growth in an evolving retail landscape. Unide faces operational challenges common to cooperative retail: manual paper label updates, inconsistent pricing, and limited promotional agility across its network. Meanwhile,

IFF Declares Dividend for Fourth Quarter 202530.10.2025 22:15:00 EET | Press release

IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on January 9, 2026 to shareholders of record as of December 19, 2025. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20251030551985/en/

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye